Prolight Diagnostics
0.162
SEK
+16.55 %
PRLD
Nordic SME
Medical Equipment & Services
Health Care
Be the first to follow this company
+16.55%
-0.61%
-32.22%
+14.08%
-46.18%
-51.79%
-86.36%
-90.74%
-62.33%
www.prolightdiagnostics.se/investor-relations
Prolight Diagnostics develops test systems in POCT (Point of care testing). The tests are used outside of hospital laboratories to enable rapid assessments of the health of patients. The company's POCT platform is under development with the intention of measuring various biomarkers simultaneously. An important component of the work is to reduce the time for test results, particularly important for patients with heart problems. The company was founded in 1999 and is based in Lund.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
Nordic SME
PRLD
Daily low / high price
0.145 / 0.17
SEK
Market cap
113.74M SEK
Turnover
4.15M SEK
Volume
27M
Financial calendar
Annual report
2025-02-21
Interim report
2025-05-14
Interim report
2025-08-28
Major OwnersSource: Millistream Market Data AB
| Owner | Capital | Votes |
|---|---|---|
| Julie Richards | 5.3 % | 5.3 % |
| Paul Brendan Monagan | 5.3 % | 5.3 % |
| Steven Andrew Ross | 5.3 % | 5.3 % |
| Aileen McGettrick | 5.3 % | 5.3 % |
| Avanza Pension | 3.9 % | 3.9 % |
| Nordic Underwriting APS | 2.8 % | 2.8 % |
| The Bank of New York Mellon, W9 | 1.9 % | 1.9 % |
| Cardeon AB | 1.6 % | 1.6 % |
| Tuvedalen Limited | 0.8 % | 0.8 % |
| Handelsbanken Livförsäkringsaktiebolag | 0.8 % | 0.8 % |
ShowingAll content types
EMERGERS VALUE PROLIGHT DIAGNOSTICS AT 730 MSEK (0,9- 1,0 SEK PER SHARE)
Emergers: Equity Research | PROLIGHT: Commercial prototype marks an important milestone towards upcoming studies
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools